Dunn David T, Glidden David V
aMRC Clinical Trials Unit at UCL, London, UK bUniversity of California, San Francisco, California, USA.
Curr Opin HIV AIDS. 2016 Jan;11(1):116-21. doi: 10.1097/COH.0000000000000218.
We discuss selected statistical issues in the design and analysis of preexposure prophylaxis (PrEP) trials. The general principles may inform thinking for other interventions in HIV prevention.
To date, four different designs have been used to determine the effectiveness of PrEP: randomized, double-blind, placebo-controlled; randomized, open-label, immediate or delayed access; nonrandomized comparison of HIV incidence according to the level of drug detected; comparison of the observed HIV incidence to the expected rate using historical control data. Open-label trials of PrEP, which assess public health effectiveness, complement the placebo-controlled trials which established the biological efficacy of TDF/FTC. Future trials of PrEP will be highly challenging to design since a no PrEP group is difficult to justify and the natural control regimen, TDF/FTC, is highly efficacious.
Standard statistical paradigms for noninferiority trials should be reconsidered for evaluating alternative PrEP regimens.
我们讨论暴露前预防(PrEP)试验设计与分析中选定的统计学问题。这些一般原则可能为思考其他HIV预防干预措施提供思路。
迄今为止,已采用四种不同设计来确定PrEP的有效性:随机、双盲、安慰剂对照;随机、开放标签、即时或延迟给药;根据检测到的药物水平对HIV发病率进行非随机比较;使用历史对照数据将观察到的HIV发病率与预期发病率进行比较。评估公共卫生有效性的PrEP开放标签试验补充了确立替诺福韦酯/恩曲他滨(TDF/FTC)生物学疗效的安慰剂对照试验。由于难以证明不使用PrEP组的合理性,且天然对照方案TDF/FTC疗效极高,未来PrEP试验的设计将极具挑战性。
在评估替代PrEP方案时,应重新考虑非劣效性试验的标准统计范式。